Answers are grounded in this paper and cite their sources.
NIR-II-responsive photozymes enhance ROS efficiency in nanocatalytic therapy, suggesting better cancer treatment options.
Nanocatalytic therapy faces limitations from low ROS efficiency and high intracellular GSH. Here a NIR-II-responsive photozyme was developed for multi-modal nanocatalytic therapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: